Breakthrough in Ophthalmology: FDA Approves Samsung Bioepis’ Biosimilar Ophthalmic Drug

by
FDA,Macular,Degeneration,Eylea,Opiforce

[su_heading size=”27″ align=”left” margin=”40″]Introduction to Macular Degeneration and Eylea[/su_heading] Macular degeneration is a severe eye condition that affects millions worldwide, primarily the elderly. This disease deteriorates the central part of the retina, called the macula, leading to vision loss. Eylea (aflibercept) is a leading treatment for macular degeneration, designed to prevent abnormal blood vessel growth … Read more

The Future of Mental Health Tracking: How Your Smartphone Keyboard Can Reveal Your Mood

by
Mental,Health,Relevance,BiAffect,Technology

[su_heading size=”27″ align=”left” margin=”40″]The Intersection of Technology and Mental Health[/su_heading] In an age where technology permeates every aspect of our lives, it’s not surprising that our gadgets can now offer insights into our mental well-being. Recent advancements by researchers at the University of Illinois have led to the development of an innovative app called BiAffect, … Read more

Strategic Moves by HLB BioStep: Enhancing Shareholder Value through Share Repurchase

by
Strategic,HLB,BioStep,Shareholders,Competencies

[su_heading size=”27″ align=”left” margin=”40″]Introduction to HLB BioStep’s Recent Actions[/su_heading] HLB BioStep, a subsidiary of HLB Group, recently announced a significant move to acquire treasury shares worth 3 billion KRW (approximately 2.5 million USD). This decision, disclosed on the 21st, is aimed at bolstering shareholder value and reflects the company’s confidence in its growth potential. The … Read more